Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty

Launched by MAYO CLINIC · Feb 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how taking a medication called Tranexamic Acid (TXA) after joint replacement surgery (known as total hip arthroplasty) might help patients recover better. The study will assess if this medication can improve how patients feel after surgery, how quickly they can start walking on their own, and if it affects their movement, swelling, and blood levels. Researchers will also monitor any complications or the need for readmission to the hospital within 90 days after the surgery.

To participate in this trial, you need to be an adult over 18 years old who is having a total hip replacement due to severe arthritis. You will need to provide written consent to join the study, and you must receive spinal anesthesia during the surgery. However, if you have a history of certain health issues, such as allergies to TXA, certain types of cancer, or if you are undergoing a different type of surgery, you may not be eligible. Participants will start the study after their surgery and will be monitored closely to see how well the medication works. This trial aims to help improve recovery experiences for future patients undergoing similar surgeries.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Adults aged \> 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
• • Written informed consent
• • Patients undergoing primary THA diagnosis of end-stage osteoarthritis
• • Patients receiving spinal anesthesia
• • Patients being discharged on postoperative day 1
• • Exclusion Criteria
• • Patients with a TXA allergy
• • Patients undergoing revision procedures
• • Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis
• • Patients receiving general anesthesia
• • Patients being discharged on the same day of surgery
• • Cancer patients
• • Patients with a history of prior VTE event
• • Patients on preoperative anticoagulants other than ASA
• • Pregnant patients (All women of child bearing potential undergo pregnancy testing prior to THA as per our institutional protocol)
• • Female patients who are on hormonal contraception
• • Patients with history of retinal vein or artery occlusion